Publications by authors named "A R Nemets"
Introduction: Waldenström macroglobulinemia (WM) is a rare indolent lymphoma. Zanubrutinib (ZAN), a second-generation BTK inhibitor, has been approved for the treatment of WM in any line of therapy in 2021. Between November 2020 and January 2022, an expanded access program of ZAN opened in Israel for the treatment of patients with relapsed/refractory (R/R)-WM or those ineligible for chemotherapy or ibrutinib in first line.
View Article and Find Full Text PDFQuality of life is impaired in MDS, but the role of hemoglobin level is unclear. To study the Hb-QoL correlation at diagnosis and 1 year later, patients filled out the EQ-5D questionnaire, assessing their mobility, self care, daily activities, pain/discomfort, and anxiety/depression, using scores of 0 (normal), 1 (mild/moderate), or 2 (poor). They also evaluated their health using a visual analogue scale, scoring from 0 (poor) to 100 (excellent).
View Article and Find Full Text PDFArticle Synopsis
- - Polatuzumab (Pola)-based regimens and CAR T cells result in better outcomes than traditional chemoimmunotherapy for patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL), but there's debate on which is more effective.
- - A retrospective study compared the efficacy of CAR T therapy to Pola-rituximab and Pola-bendamustine in patients who had undergone at least two prior treatments, using propensity score matching for accurate comparison.
- - Results showed that CAR T had higher overall (83% vs. 66%) and complete response rates (58% vs. 44%), and significantly longer progression-free survival (PFS) and overall survival (OS
Multiple myeloma (MM) is a neoplastic plasma-cell disorder characterized by clonal proliferation of malignant plasma cells. Despite extensive research, disease heterogeneity within and between treatment-resistant patients is poorly characterized. In the present study, we conduct a prospective, multicenter, single-arm clinical trial (NCT04065789), combined with longitudinal single-cell RNA-sequencing (scRNA-seq) to study the molecular dynamics of MM resistance mechanisms.
View Article and Find Full Text PDFArticle Synopsis
- * Results showed a 61% overall response rate, with 40% achieving complete responses and a median overall survival of 8.3 months, indicating positive outcomes for this treatment.
- * Factors like poor Eastern Cooperative Oncology Group performance status and primary refractory disease were linked to shorter survival and progression-free survival, highlighting their impact on treatment outcomes.